-+ 0.00%
-+ 0.00%
-+ 0.00%

Prelude Therapeutics Q3 EPS $(0.26) Beats $(0.36) Estimate, Sales $6.500M Up From $3.000M YoY

Benzinga·11/12/2025 12:06:45
Listen to the news
Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.36) by 28.77 percent. This is a 39.53 percent increase over losses of $(0.43) per share from the same period last year. The company reported $6.500 million in sales this quarter. This is a 116.67 percent increase over sales of $3.000 million the same period last year.